Population-based studies of the epidemiology of benign prostatic hyperplasia

British Journal of Urology

Volumn 82, Issue SUPPL. 1, 1998, Pages 34-43

  Girman, C J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Ageing; Benign prostatic hyperplasia; Community studies; Epidemiology

Indexed keywords

HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; SENESCENCE; SYMPTOM; URINE FLOW RATE; URINE RETENTION;

ADULT; AGED; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; PROSTATIC HYPERPLASIA; URINARY RETENTION; URINATION; UROLOGIC SURGICAL PROCEDURES;

EID: 0031761149     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1998.0820s1034.x     Document Type: Article

References (114)

1. McKelvie (IB. CoIIins CN. Hehir M. Rogers AC. A study of benign prostalic hyperplasia - a challenge to British urology. Br ] U ml 1993; 71: 38-42
2. Oesterling JE. Benign prostatie hyperplasia: a review of its histogenesis and natural history. The Prostate 1996: 6: f>7-73
3. Guess HA. Benign prostatie hyperplasia: antecedents and natural history. Lfiideniiol Ri'v 1992: 14: 1 31-53
4. MeC'onnell JD. Barry M). Bruskevvitz RC: Benign Frostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice
5. Guideline, Number 8, AHCPR Publication No. 94-0582. Rockville. Maryland: Agency for Health Care Policy and Research, Public Health Service, United States Department of Health and Human Services. February 1994.
6. Oishi K, Boyle P, Barry MJ, et al. Epidemiology and Natural History of Benign Prostatic Hyperplasia. In: Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Denis L. Griffiths K, Khoury S. Cockett ATC, McConnell J. Châtelain C. Murphy G. Yoshida 0 (eds). Scientific Communication International Ltd, 1998.
7. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990: 17: 495-507
8. Meigs JB, Barry MJ. Natural history of benign prostatic hyperplasia. In Kirby R. McConnell J, Fitzpatrick J. Roehrborn C, Boyle P. eds, Textbook of Benign Prostatic Hyperplasia. Oxford: Isis Medical Media Ltd 1996: 125-35
9. Guess HA, Jacobsen SJ, Girman CJ et al. The role of community-based longitudinal studies in evaluating treatment effects. Example: benign prostatic hyperplasia. Med Care 1995: 33: AS26-AS35
10. Hald T. Urodynamics in benign prostatic hyperplasia. A survey. Prostate 1989: 2 (Suppl): 69-77
11. Chai TC, Belville WD. McGuire EJ, Nyquist L. Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 1993: 150: 1710-3
12. Chancellor MB. Rivas DA. American Urological Association symptom index for women with voiding symptoms: lack of index specificity for benign prostatic hyperplasia. J Urol 1993: 150: 1706
13. Lepor H. Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993: 42: 36
14. Abrams P. New words for old: lower urinary tract symptoms for "prostatism' [editorial]. Br Med J 1994; 9308: 929-30
15. Barry MJ. Boyle P, Fourcroy J et al. Epidemiology and natural history of BPH. In: Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey: Scientific Communication International Ltd 1996
16. McPherson K. Wennberg J. Hovind O. Clifford P. Small area variations in the use of common surgical procedures: an international comparison of New England. England, and Norway. N Engl J Med 1982: 307: 1310-4
17. Wennberg JE. Mulley AGJ, Hanley D et al. An assessment of prostatectomy for benign urinary tract obstruction: Geographic variations and the evaluation of medical care outcomes. JAMA 1988; 259: 3027-30
18. Jacobsen SJ. Girman CJ. Guess HA, Oesterling JE. Lieber MM. Do prostate size and urinary flow rates predict health care seeking behavior for urinary symptoms in men? Urology 1995; 45: 64-9
19. Girman CJ. Jacobsen SJ, Guess HA et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995: 153: 1510-5
20. Girman CJ. Epidemiology of benign prostalic hyperplasia - relationship among urologie measures. Urology 1998; 51 (Suppl.): 8-12
21. Sech SM. Montoya JD. Bernier PA et al. The so-called placebo effect' in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology 1998: 51: 242-50
22. Chute CG. Panser LA. Girman CJ cl al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85
23. Garraway WM. Collins GN. Lee RJ. High prevalence of benign prostatic hyperplasia in the community. Lancet 1991: 338: 469-71
24. Jacobsen SJ, Guess HA. Panser L, Girman CJ, Oesterling JE, Lieber MM. A population-based study of health care-seeking behavior for treatment of urinary symptoms. Arch Fain Med 1993; 2: 729-35
25. Sagnier PP, Girman CJ, Garraway WM et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Ear Urol 1996; 29: 15-20
26. 5 Tsukamoto T. Kumamoto Y. Masumori N et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995: 154: 391-5
27. Barry MJ. Fowler FJ Jr. O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992: 148: 1549
28. Abrahamson ZH. Gofin J. Abramson JH. Obstructive prostatic symptoms: a community survey in Jerusalem. Int J Epidemiol 1994; 23: 797-804
29. Bosch JLHR, Hop WCJ, Kinkels WJ. Schröder FH. The International Prostate Symptom Score in a community-based sample of men between fifty-five and seventy-four years of age. Prevalence and correlation of symptoms with age. prostate volume, flow rate and residual urine Vol. Br J Urol 1995: 75: 622-30
30. Britton JP, Dowell AC, Whelan P. Prevalence of urinary symptoms in men aged over 60. Br J Urol 1990; 66: 175-6
31. Chicharro-Molero JA. Burgos-Rodriguez R, Sanchez-Cruz JJ. Del Rosal-Samaniego JM. Rodero-Carcia P. Rodriguez-Vallejo JM. Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. J Urol 1998; 159: 878-82
32. Choi H-R. Song JM. Hong SJ et al. The prevalence of prostatism in Korea: Factors affecting I-PSS. J Urol 1996; 155: 631A
33. Diokno A. Brown M. Goldstein N. Herzog A. Epidemiology of bladder emptying symptoms in elderly men. J Urol 1992: 148: 1817-21
34. Hunter DJW. Berra-llnamuno A. Martin-Gordo A. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years or older. J Urol 1996; 155: 1965-70
35. Hunter DJW. McKee CM. Black NA. Sanderson CF. Urinary symptoms: prevalence and severity in British men aged 55 and over. J Epidemiol Comm Health 1994; 48: 569-75
36. Jolleys JV. Donovan JL. Nanchahal K. Peters TJ. Abrams P. Urinary symptoms in the community: how bothersome are they? Br J Uwl 1994: 74: 551-5
37. Koskimaki J. Hakama M. Huhtala H. Tammela TIJ. Prevalence of lower urinary tract symptoms in Finnish men: a population-based study. Br J Urol 1998: 81: 364-9
38. Moon H-J. Moon W-C, Seo K-K. Kim YS. High prevalence of proslatism and benign prostatic hyperplasia in Korean men. J Urol 1995: 155: 631A
39. Nacey JM. Morum P. Delahunt B. Analysis of the prevalence of voiding symptoms in Maori. Pacific Island, and Caucasian New Zealand men. Urology 1995: 46: 506-11
40. Overland GB. Vada K. Vatten IJ. Prostate volume, peak urinary flow rate, residual urine, urinary symptoms and benign hyperplasia of the prostate in a population-based study in Norway. J Urol 1997: 157: 373
41. Sommer P. Nielsen KK. Bauer T et al. Voiding patterns in men evaluated by a questionnaire survey. Br J Urol 1990: 65: 155-60
42. Tan HY. Choo WO Archibald C. Esuvaranathan K. A community based study of prostatic symptoms in Singapore. J Urol 1997: 157: 890-3
43. Wolfs GGMC. Knottnerus JA. Janknegt RA. Prevalence and detection of micturition problems among 2.734 elderly men. J LTD/ 1994: 152: 1467-70
44. Guess HA, Chute CCi. (îarraway WM cf al. Similar levels of urological symptoms have similar impact on Scottish and American men-although Scots report less symptoms. J Urol 1993: 150: 1701-5
45. Roberts RO. Rhodes T. Panser LA. et al. Natural History of Prostatism: Worry and Embarrassment from Urinary Symptoms and Health Care Seeking Behavior. Uroloait 1994: 43: 621-8
46. Stimson JB. Film SI). Benign prostalic hyperplasia and its treatment. J Gen Intern Med 1990: 5: 153-65
47. Su L. Guess HA. Qrman CJ. Jacobsen SJ. Panser LA. Lieber MM. Adverse effects of medications on symptoms of benign prostalic hyperplasia: A community-based study. J Clin Epidemwl 1996: 49: 483-7
48. Norman RW. Nickel JC. Fish D. Picket! SN. 'Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 1994: 74: 542-50
49. Jacobsen SJ, Ĝirman CJ. Guess HA cf a\. Natural history of prostatism. Longitudinal changes in voiding symptoms in community-dwelling men. / Urol 1996: 155: 595-600
50. Jacobsen SJ. Jacobson DJ. Girman CJ. Roberts RO. Guess HA. Lieber MM. Natural history of prostatism: 5-year longitudinal changes in lower urinary tract symptom severity. J Urol 1998: 159 (Suppl.): 524
51. Barry MJ. Fowler FJ Jr. Bin L. I'itts III JC. Harris CJ. Mulley AG Jr. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997: 157: 10-5
52. Girman CJ. Panser LA. Chute CG. Guess HA. Oesterling JF. Lieber MM. Natural history of proslatism: urinary flow rates in a community-based study. J Urol 1993: 150: 887-92
53. Haylen ET. Ashby D. Suther.st JR. Frazer Ml. Wust CR. Maximum and average urine flow rates in normal male and female populations - the Liverpool nomograms. Kr J Urol 1989: 64: 30
54. Jorgensen JB. Jensen KM-L. Bille-Bralie N F.. Mogensen P. Urotlowmetrv in asymptomatic elderly males. Br J I; nil 1986: 58: 390-5
55. Masumori N. Tsukamoto T. Kumamoto Y et al. Japanese men have smaller prostate volumes but comparable urinary How rates relative to American men - results of community-based studies in two countries. J Urol 1996: 155: 1324-7
56. Golomb J. I.indner A. Siegel Y. Korczak D. Variability and circadian changes in home uroflowmetry in patients with benign prostatic hyperplasia compared to normal controls. J Urol 1992: 147: 1044
57. Barry MJ. Girman CJ. O'Leary MF et al. Using repeated measures of symptom score, uroflow. and prostate specific antigen in the clinical management of prostate disease. J Urol 1995; 153: 97-103
58. Diokno AC. Brown MB. Goldstein NG. Herzog AR. Urinary flow rates and voiding pressures in elderly men living in a community. J Urol 1994: 151: 1550-3
59. Siroky MB. Interpretation of urinary flou rates. U ml Clin J Am 1990: 17: 537
60. Siroky MB. Olsson CA. Krane R|. The How rate nomogram. I. Development. J Urol 1979: 122: 665
61. von Garrelts B. Micturition in the normal male. Acta Cliir Scand 1957: 114: 197
62. Roberts RO. Jacobsen SJ. Jacobson DJ et al. Natural history of prostatism in a community-based cohort of men: Longitudinal decline in peak urinary flow rates is greater than expected. J Urol 1998: 159 (Suppl.): 427
63. Berry SJ. Coffey US. Walsh PC ct til. The development of human prostatic hyperplasia with age. J Urol 1984: 152: 474-9
64. Guess HA. Arrighi HM. Metter LJ et al. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. I'rostati' 1990: 17: 241-6
65. Bosch |LHR, Hop \VC[. Niemer OHJ ri al. Parameters of prostate volume and shape in a community-based population of men 55 to 74 years old. / Urol 1994: 152: 1501-5
66. Collins (iN. Lee RJ. Russell KB. Raab CAL Hehir M. I Itrasonically determined patterns of enlargement in benign prostatic hyperplasia. Br }Ural 1993: 71: 451
67. Jakobsen II. Torp-Pedersen S. Juul N. Ultrasonic evaluation of age-related human prostatic growth and development of benign prostatic hyperplasia. Scwiil / Urol ,\e/>/iroJ Suppl 1988: 107: 26-31
68. Oesterling JL, Jacobsen SJ. Chute CG et al. Serum prostatespecilic antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. //UH 1993: 270: 860-4
69. Ohnishi K, Watanabe H. Ohé H. Development of benign prostatic hypertrophy estimated from ultrasonic measurements with long-term follow-up. Tolioku / E\p Mcd 1987: 151: 51-5
70. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA. Lieber MM. Longitudinal Measures of Prostate Volume in a Community-Based Sample: 5.5 Year Follow-up in the Olmsted County Study of Urinary Symptoms and Health Status Among Men. / Urol 1998: 159 (Suppl):525
71. Rhodes T. Girman CJ. Jacobsen SJ. Guess HA. Oesterling JE. Lieber MM. Longitudinal prostate growth rates over five years in men aged 40-79 years. / Urol in press
72. Abrams PH, Feneley RCL. The significance of symptoms associated with bladder outflow obstruction. Urol Int 1978: 33: 171
73. Barry MJ, Cockett ATK. Holtgrewe HL. McConnell JD. Sihelnik SA. Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150: 351
74. Christiansen MM, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin N Am 1990: 17: 509
75. Graversen PH, Gasser TC, Wasson JH. Hinman F Jr. Bruskewitz RC. Controversies about indications for transurethral resection of the prostate. J Urol 1989: 141: 75
76. Jensen KM. Jorgensen JB. Mogensen P, Bille-Brahe NE. Some clinical aspects of urofiowmetry in elderly males. A population survey. Scand J Urol Nephrol 1986; 20: 93
77. Jensen KME, Bruskewitz RC. Iversen P. Madsen PO. Significance of prostate weight in prostatism. Urol Int 1983; 38: 173
78. Collins GN, Raab GM. Hehir M. King B. Garraway WM. Observer variability and reproducibility of transrectal ultrasound in the measurement of prostate volume. Ultrasound Med Biol 1995; 21: 1101-5
79. Wilson IB. Cleary PD. Linking clinical variables with health-related quality of life. JAMA 1995; 273: 59
80. McConnell JD, Roehrborn CG. Patient selection and symptom evaluation. In Chisholm GD, ed. Handbook on benian prostatic hyperplasia. Whitehouse Station. NJ: Merck & Co.. Inc. 1994
81. Ball AJ. Feneley RCL, Abrams PH. The natural history of untreated 'prostatism'. Br J Urol 1981: 53: 613-6
82. Birkhoff JD. Wiederhorn AR. Hamilton ML. Zinsser HH. Natural history of benign prostatic hypertrophy and acute urinary retention. Urology 1976; 7: 48-52
83. Craigen AA, Hickling JB. Saunders CRG. Carpenter RG. Natural history of prostatic obstruction. J Roy; Coll Gen Pract 1969: 18: 226-32
84. Breum L. Klarskov P, Munck LK, Nielsen TH, Nordestgaard AG. Significance of acute urinary retention due to infravesical obstruction. Scand J Urol Nephrol 1982; 16: 21-4
85. Hastie KJ. Dickinson A], Ahmad R, Moisey CU. Acute urinary retention of urine: is trial without catheter justified? J Roy Coll Surg Edinb 1990: 35: 225-7
86. Klarskov P, Andersen JT, Asmussen CF et al. Symptoms and signs predictive of the voiding pattern after acute urinary retention in men. Scand }Urol Nephrol 1987; 21: 23-8
87. Wasson J. Reda D, Bruskewitz R, Elinson J. Keller AM. Henderson WG for the Veterans Affairs Cooperative Study
88. Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl ) Med 1994: 332: 75-9
89. Roehrborn CG, Oesterling JE. Auerbach S et al. for the HYCAT Investigator Group. The Hytrin Community Assessment Trial Study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996; 47: 159-68
90. Somers WJ, Mora M], Mason MF, Padley RJ for the HYCAT Investigators Group. The natural history of benign prostatic hypertrophy: Incidence of urinary retention and significance of AUA symptom score. / Urol 1996; 155: 586
91. Andersen JT, Nickel JC, Marshall VR. Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997; 49: 839-45
92. McConnell JO, Bruskewitz R, Walsh P et al. for the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl ] Med 1998: 338: 557-63
93. Powell PH. Smith PJB. Feneley RCL. The identification of patients at risk for acute retention. Br ] Urol 1980: 53: 520-2
94. Andersen JB. Grant JBF. Postoperative retention of urine: A prospective urodynamic study. Br Med }1991: 302: 894-6
95. O'Flynn JD. The management of simple prostatic hyperplasia. Br }Hasp Med 1969: 1: 562-70
96. Jacobsen SJ. Jacobson DJ, Girman CJ et al. Natural history of prostatism: Risk factors for acute urinary retention. / Urol 1997: 158: 481-7
97. Jacobsen SJ. Jacobson ÜJ, Girman CJ et al. Natural history of prostatism. urologie complications in communitydwelling men. / General Intern Med 1997: 12: 53
98. Grosse H. Frequency localization and associated disorders in urinary calculi. Analysis of 1671 autopsies for urolithiasis. Z Urol Nephrol 1990: 83: 469-74
99. Lipsky BA. Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis treatment. Ann Intern Med 1989: 110: 138-50
100. Makumel E. Nissenkorn I, Boner G. Servadio C. Occult progressive renal damage in the elderly male due to benign prostatic hypertrophy. / Am Geriatr Soc 1979; 27: 403-6
101. Chisholm GD. Obstructive nephropathy. Functional abnormalities and clinical presentation. Prof R Soc Med 1970; 63: 1242-5
102. Kaufman J, Dhakal M. Patel B. Hamburger R. Communityacquired acute renal failure. Am J Kidney Dis 1991: 17: 191-8
103. DuBeau CE, Resnick NM. Controversies in the diagnosis and management of benign prostatic hypertrophy. Adv hit Med 1991; 37: 55-83
104. Mebust WK et al. Transurethral prostatectomy: Immediate and postoperative complications: A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243
105. Lu-Yiio CL. Barry MJ. Chang C-H. Wasson JH. Wennberg JE and the Prostate Patient Outcomes Research Team (PORT). Transurethral resection of the prostate among Medicare heneticiaries in the United States: Time trends and outcomes. Urology 1994; 44: 692-8
106. Bruskevvitz RC. Reda DJ. Wasson JH. Barrett L. Phelan M. Testing to predict outcome alter transurethral resection of the prostate. J Urol 1997: 157: 1304-8
107. Flanigan RC. Reda DJ. Wasson JH. Anderson RJ. Abdellatif M. Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia. A Department of Veterans Affairs Cooperative Study. J Urol 1998; 160: 12-7
108. Arrighi HM. Guess HA. Metter EJ. Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. The Prostate 1990: 16: 253-61
109. Glynn RJ. Campion F.W. Bouchard GR et al. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985; 121: 78-90
110. Epstein R, Lydick H. DeLabry L. Vokonas P. Age-related differences in risk factors for prostateclomy for benign prostatic hyperplasia. The VA Normative Aging Study. L'rolofifi 1991: 38: 59-62
111. Sidney S. Ouesenberry CP. Sadler MC. Guess HA. I.ydick EG. Cattolica FA'. Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan. Am J Epid 1991: 134: 825-9
112. Morrison AS. Risk factors for surgery for prostatic hypertrophy. Am J Epidcmiol 1978: 135: 974
113. Jorgensen JB. Jensen KM. Mogensen P. Long-term probability of prostatism vs. general morbidity and mortality. Scand Uivl \epliwl 1994: 28: 165-9
114. C. Girman, DrPH, Senior Investigator Merck Research Laboratories. Department of Epidemiology. BL1-7. PO Box 4. West Point. PA 19486. USA girman@merck.com